Ventyx’s Parkinson’s Pill Shows ‘Promising’ Results in Mid-Stage Study, Paving Path to Other Neuro Diseases

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including Alzheimer’s.